Related Experiment Videos
Hemiparkinsonism-somatic hemiatrophy syndrome
Mary Jenkins1, Dan Mendonca, Andrew Parrent
1Department of Clinical Neurological Sciences, London Health Sciences Centre, ON, Canada.
Summary
Hemiparkinsonism-hemiatrophy (HPHA) is a distinct parkinsonian syndrome. Subthalamic nucleus stimulation showed dramatic improvement in a patient unresponsive to medications, suggesting early surgical intervention for HPHA.
Area of Science:
- Neurology
- Neurosurgery
Background:
- Hemiparkinsonism-hemiatrophy (HPHA) syndrome presents uniquely within the parkinsonian spectrum.
- Understanding HPHA's distinct clinical and pathophysiological mechanisms is crucial.
Observation:
- A case study of a 21-year-old woman with HPHA is presented.
- The patient exhibited unilateral parkinsonism and hemiatrophy.
- Conventional medications offered no benefit.
Findings:
- Subthalamic nucleus (STN) stimulator implantation resulted in dramatic improvement.
- This represents the first reported case of STN stimulator use in HPHA.
- HPHA may differ clinically and pathogenetically from idiopathic Parkinson's disease.
Implications:
- HPHA should be considered in persistent unilateral parkinsonism.
- Early surgical intervention, such as STN stimulation, may be a viable treatment option for HPHA.
- Further research into HPHA's unique characteristics and treatment is warranted.